Bone Biologics CorpBBLG
Price$0.47

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$2.9MTTM through 31 Mar 2026
Free Cash Flow -$2.6MTTM through 31 Mar 2026

Margins

Current

Returns

-75.4%ROE
-46.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio16.09x
Net Debt-$4.5Mnet cash position
Cash & Equivalents$4.5M

Quality Metrics

Earnings-Beat Rate50.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Orthobiologics Development$0
View details

Focusing on advancing the multicenter, prospective, randomized pilot clinical study of NB1 in degenerative disc disease in Australia.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.